Micellae Delivery Systems Inc.

Micellae Delivery Systems Inc. is a technology-based company that specializes in advanced drug delivery systems designed to improve the solubility and bioavailability of hydrophobic bioactive compounds. Founded as a spinout from the University of Toronto based on 15 years of research, the company developed O2W, a proprietary Self-Microemulsifying Drug Delivery System (SMEDDS). This technology is designed to be free of Polyethylene Glycols (PEGs) and uses food-grade excipients to enhance the performance, onset speed, and safety of formulations. Their platform is adaptable for various dosage forms, including concentrates, powders, and gels, providing a tunable-release profile for high-potency products.

The company primarily serves pharmaceutical, medical, and recreational cannabis producers, helping them create safer, more sustainable, and high-performing products. By solving the challenge of low oral bioavailability in cannabinoids—which typically suffer from poor absorption in the gastrointestinal tract—Micellae’s technology aims to deliver therapeutic effects more efficiently to consumers and patients. The firm actively engages with industry partners to integrate O2W into existing or new product lines, supported by a foundation of academic research, granted patents, and peer-reviewed scientific publications that validate their formulation expertise.